Hon Dr MEGAN WOODS: Early indications from clinical trials of vaccine candidates show the effectiveness is higher than had previously been expected, which is promising. For example, one of the candidates we have secured—Pfizer BioNTech—has been reported at 90 percent effectiveness. However, safety will always be our absolute priority, and we will not be rushed into accepting the first vaccine that shows promise. Vaccine candidates will be assessed through our own regulatory processes before they are distributed to the community. 